Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term Epidermal Growth Factor Receptor. Found 23 abstracts

no pagination
Galloway TJ, Wirth LJ, Colevas AD, Gilbert J, Bauman JE, Saba NF, Raben D, Mehra R, Ma AW, Atoyan R, Wang J, Burtness B, Jimeno A. A Phase I Study of CUDC-101, a Multitarget Inhibitor of HDACs, EGFR, and HER2, in Combination with Chemoradiation in Patients with Head and Neck Squamous Cell Carcinoma. Clin Cancer Res. 2015 Apr;21(7):1566-73.
Ali SM, Alpaugh RK, Buell JK, Stephens PJ, Yu JQ, Wu H, Hiemstra CN, Miller VA, Lipson D, Palmer GA, Ross JS, Cristofanilli M. Antitumor response of an ERBB2 amplified inflammatory breast carcinoma with EGFR mutation to the EGFR-TKI erlotinib. Clin Breast Cancer. 2014 Feb;14(1):e14-6.
Astsaturov I, Ratushny V, Sukhanova A, Einarson MB, Bagnyukova T, Zhou Y, Devarajan K, Silverman JS, Tikhmyanova N, Skobeleva N, Pecherskaya A, Nasto RE, Sharma C, Jablonski SA, Serebriiskii IG, Weiner LM, Golemis EA. Synthetic lethal screen of an EGFR-centered network to improve targeted therapies. Science signaling. 2010 Jan;3(140):ra67.   PMCID: PMC2950064
Cristofanilli M, Valero V, Mangalik A, Royce M, Rabinowitz I, Arena FP, Kroener JF, Curcio E, Watkins C, Bacus S, Cora EM, Anderson E, Magill PJ. Phase II, randomized trial to compare anastrozole combined with gefitinib or placebo in postmenopausal women with hormone receptor-positive metastatic breast cancer. Clinical Cancer Research. 2010 Mar 15;16(6):1904-14.   PMCID: NIHMS352308
Li L, Quang TS, Gracely EJ, Kim JH, Emrich JG, Yaeger TE, Jenrette JM, Cohen SC, Black P, Brady LW. A Phase II study of anti-epidermal growth factor receptor radioimmunotherapy in the treatment of glioblastoma multiforme. J Neurosurg. 2010 Aug;113(2):192-8.   PMCID: not NIH funded
Ratushny V, Astsaturov I, Burtness BA, Golemis EA, Silverman JS. Targeting EGFR resistance networks in head and neck cancer. Cell Signal. 2009 Aug;21(8):1255-68.   PMCID: PMC2770888
Schilder RJ, Sill MW, Lee YC, Mannel R. A phase II trial of erlotinib in recurrent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group Study. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society. 2009 Jul;19(5):929-33.   PMCID: PMC2722934
Astsaturov I, Cohen RB, Harari PM. Clinical application of EGFR inhibitors in head and neck squamous cell cancer. Cancer Treat Res. 2008 Jan;139:135-52.
Borghaei H, Langer CJ, Millenson M, Ruth KJ, Litwin S, Tuttle H, Seldomridge JS, Rovito M, Mintzer D, Cohen R, Treat J. Phase II study of paclitaxel, carboplatin, and cetuximab as first line treatment, for patients with advanced non-small cell lung cancer (NSCLC): results of OPN-017. J Thorac Oncol. 2008 Nov;3(11):1286-92.
Langer CJ. Targeted therapy in head and neck cancer: state of the art 2007 and review of clinical applications. Cancer. 2008 Jun 15;112(12):2635-45.
Mehra R, Cohen RB, Harari PM. EGFR inhibitors for the treatment of squamous cell carcinoma of the head and neck. Current oncology reports. 2008 Mar;10(2):176-84.
Sengupta S, Jordan VC. Selective estrogen modulators as an anticancer tool: mechanisms of efficiency and resistance. Advances in experimental medicine and biology. 2008 Jan;630:206-19.
Ariazi EA, Kraus RJ, Farrell ML, Jordan VC, Mertz JE. Estrogen-related receptor alpha1 transcriptional activities are regulated in part via the ErbB2/HER2 signaling pathway. Molecular cancer research : MCR. 2007 Jan;5(1):71-85.
Astsaturov I, Cohen RB, Harari P. EGFR-targeting monoclonal antibodies in head and neck cancer. Curr Cancer Drug Targets. 2007 Nov;7(7):650-65.
Denlinger CS, Cohen SJ. Progress in the development of prognostic and predictive markers for gastrointestinal malignancies. Current treatment options in oncology. 2007 Oct;8(5):339-51.
Forastiere AA, Burtness BA. Epidermal growth factor receptor inhibition in head and neck cancer--more insights, but more questions. J Clin Oncol. 2007 Jun;25(16):2152-5.
Langer CJ. Mind your elders: therapeutic implications of epidermal growth factor receptor inhibition in older patients with advanced non-small-cell lung cancer. J Clin Oncol. 2007 Mar;25(7):751-3.
Kim SH, Nakagawa H, Navaraj A, Naomoto Y, Klein-Szanto AJ, Rustgi AK, El-Deiry WS. Tumorigenic conversion of primary human esophageal epithelial cells using oncogene combinations in the absence of exogenous Ras. Cancer Res. 2006 Nov;66(21):10415-24.
Damjanov N, Meropol NJ. Epidermal growth factor receptor inhibitors for the treatment of colorectal cancer: a promise fulfilled?. Oncology (Williston Park). 2004 Apr;18(4):479-88; discussion 488, 493.
Langer CJ. Emerging role of epidermal growth factor receptor inhibition in therapy for advanced malignancy: focus on NSCLC. Int J Radiat Oncol Biol Phys. 2004 Mar;58(3):991-1002.
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term Epidermal Growth Factor Receptor

Epidermal Growth Factor Receptor drug therapy therapeutic use Squamous Cell Carcinoma Monoclonal Antibodies metabolism Quinazolines antagonists & inhibitors Head and Neck Neoplasms Female genetics Middle Aged Aged pathology methods Antineoplastic Agents Combined Modality Therapy Protein Kinase Inhibitors Survival Rate Treatment Outcome drug effects Male antagonists & Breast Neoplasms Prognosis Neoplasm Drug Resistance Non-Small-Cell Lung Carcinoma Lung Neoplasms Estrogen Receptors analysis Adult inhibitors pharmacology secondary radiotherapy administration & adverse effects Progesterone Receptors Apoptosis dosage erbB-2 Receptor 80 and over Aged Drug Delivery Systems Proto-Oncogene Proteins c-akt Maximum Tolerated Dose Neoplasm Metastasis physiology Cisplatin Prospective Studies Gene Expression Profiling mortality Signal Transduction immunology administration & dosage Clinical Trials as Topic Human ras Genes Mutation 0 (Quinazolines) Uterine Cervical Neoplasms Nitriles Radioimmunotherapy Protein Kinase C Age Factors Chemoradiotherapy blood Electrophoretic Mobility Shift Assay Multivariate Analysis Small Interfering RNA Cytotoxins Neoplasm Circulating Cells Postmenopause Hydroxamic Acids Clinical Trials Microsatellite Instability Presenilin-2 Immunohistochemistry Proportional Hazards Models Dacarbazine ai [Antagonists & Inhibitors] Protein-Tyrosine Kinase ai [Antagonists & Oncogenes Young Adult Protocols bcl-X Protein Biological Models Paclitaxel DNA-Binding Proteins therapy etiology 184475-35-2 (gefitinib) Transformed Cell Line myc Genes Phosphorylation ErbB-2 Receptor Brain Neoplasms Neoplastic Gene Expression Regulation Adenocarcinoma Radiotherapy Double-Blind Method Her2 Nuclear Receptor Coactivator 2 Thymidine Phosphorylase Heterologous Transplantation Cultured Tumor Cells Predictive Value of Tests Protein Interaction Mapping Neoplasm Transplantation Antineoplastic Combined Chemotherapy Protocols Carcinoembryonic Antigen Drug Discovery Alkylating Antineoplastic Agents Polymerase Chain Reaction Kaplan-Meiers Estimate Cell Cycle Carboplatin analogs & Antineoplastic Combined Chemotherapy Inflammatory Breast Neoplasms Quality of Life Genetic Transcription Peptide Receptors Neoplasm Proteins 0 (erlotinib) Immunotherapy Gastrointestinal Neoplasms pharmacokinetics Epithelial Cells EC 2-7-1-112 (Protein-Tyrosine Kinase) Histone Deacetylases Biological Tumor Markers Lymphatic Metastasis Hormone-Dependent Neoplasms STAT3 Transcription Factor 0 (Antineoplastic Agents) Mitogen-Activated Protein Kinase Kinases Neoplasm Staging Neoplastic Cell Transformation Medical Oncology Inbred BALB C Mice Mice Tissue Distribution tu [Therapeutic Use] Adjuvant Radiotherapy Guanylate Cyclase Lapatinib Antibody-Dependent Cell Cytotoxicity Endonucleases Gene Dosage
Last updated on Friday, March 02, 2018